Georgios Vlachogiannis

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance through a One-to-Many Genotype-to-Phenotype Paradigm.

Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance through a One-to-Many Genotype-to-Phenotype Paradigm.

Journal: Cancer research

Published: March 04, 2025

Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.

Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.

Journal: Cancer discovery

Published: June 11, 2024

Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line Chemotherapy.

Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line Chemotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 30, 2024

Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.

Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 16, 2023

USP7 inactivation suppresses APC-mutant intestinal hyperproliferation and tumor development.

USP7 inactivation suppresses APC-mutant intestinal hyperproliferation and tumor development.

Journal: Stem cell reports

Published: March 29, 2022

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer.

A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: July 27, 2021

MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer.

MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer.

Journal: Cell death and differentiation

Published: October 13, 2020

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.

Journal: Gut

Published: July 28, 2020

MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression.

MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression.

Journal: Cancer discovery

Published: May 12, 2020

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.

Journal: Nature communications

Published: October 08, 2019

Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.

Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.

Journal: Nature communications

Published: October 01, 2019

Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.

Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.

Journal: Hepatology (Baltimore, Md.)

Published: July 31, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026